Recurrent Glioblastoma Clinical Trial
Official title:
Fluoroethyltyrosine for the Evaluation of Intracranial Neoplasm
This phase II trial studies how well F-18 fluoroethyltyrosine (fluoroethyltyrosine) works in detecting tumors in participants with intracranial tumors that have come back. FET accumulates in malignant cells within intracranial neoplasms and can be used to detect recurrent disease and characterize the grade of glial neoplasms. Imaging agents such as FET can help oncologist to see the tumor better during a positron emission tomography (PET) scan.
PRIMARY OBJECTIVES: I. To determine if F-18 fluoroethyltyrosine (FET) PET can differentiate between benign treatment-related changes and recurrence in comparison to pathology in population 1 with recurrent metastatic disease and high-grade gliomas. II. To determine if FET PET can accurately differentiate between low-grade and high-grade gliomas in population 2. SECONDARY OBJECTIVES: I. To determine if FET PET can differentiate between benign treatment-related changes and recurrence in comparison to pathology or imaging follow-up in population 1. II. To determine if FET PET can differentiate between benign treatment-related changes and recurrence in comparison to pathology in population 1 with recurrent low-grade gliomas. OUTLINE: Participants receive F-18 fluoroethyltyrosine intravenously (IV) over approximately 1 minute and undergo PET over 40 minutes. After completion of study treatment, participants are followed up periodically. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05577091 -
Tris-CAR-T Cell Therapy for Recurrent Glioblastoma
|
Phase 1 | |
| Recruiting |
NCT05284643 -
Spectroscopic MRI, Proton Therapy, and Avastin for Recurrent Glioblastoma
|
N/A | |
| Recruiting |
NCT05039281 -
Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04988750 -
Evaluate the Safety and Preliminary Efficacy of the Combination of NaviFUS System With Re-irradiation for rGBM Patients
|
N/A | |
| Recruiting |
NCT06058988 -
Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer
|
Phase 2 | |
| Completed |
NCT00503204 -
Phase I : Cediranib in Combination With Lomustine Chemotherapy in Recurrent Malignant Brain Tumour
|
Phase 1 | |
| Completed |
NCT03216499 -
HIF-2 Alpha Inhibitor PT2385 in Treating Patients With Recurrent Glioblastoma
|
Phase 2 | |
| Not yet recruiting |
NCT04717999 -
Pilot Study of NKG2D CAR-T in Treating Patients With Recurrent Glioblastoma
|
N/A | |
| Not yet recruiting |
NCT05540275 -
Tislelizumab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for Bevacizumab Refractory Recurrent Glioblastoma
|
Phase 2 | |
| Recruiting |
NCT04528680 -
Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel and Carboplatin for Recurrent Glioblastoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04888611 -
Neoadjuvant PD-1 Antibody Alone or Combined With DC Vaccines for Recurrent Glioblastoma
|
Phase 2 | |
| Completed |
NCT00390299 -
Viral Therapy in Treating Patients With Recurrent Glioblastoma Multiforme
|
Phase 1 | |
| Recruiting |
NCT05463848 -
Surgical Pembro +/- Olaparib w TMZ for rGBM
|
Phase 2 | |
| Active, not recruiting |
NCT04479241 -
LUMINOS-101: Lerapolturev (PVSRIPO) and Pembrolizumab in Patients With Recurrent Glioblastoma
|
Phase 2 | |
| Active, not recruiting |
NCT00777153 -
Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma
|
Phase 3 | |
| Withdrawn |
NCT05017610 -
Inducing a Hypothyroxinemic State in Patients With Recurrent Glioblastoma or Gliosarcoma
|
Early Phase 1 | |
| Recruiting |
NCT04323046 -
Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults
|
Phase 1 | |
| Active, not recruiting |
NCT05324501 -
A Study of Intra-tumoral Administered MTX110 in Patients With Recurrent Glioblastoma
|
Phase 1 | |
| Withdrawn |
NCT05666349 -
Reirradiation and Niraparib in Patients With Recurrent Glioblastoma
|
Phase 1 | |
| Active, not recruiting |
NCT04440358 -
Exablate Blood-Brain Barrier Disruption With Carboplatin for the Treatment of rGBM
|
Phase 1/Phase 2 |